Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.43 |
| ▸ | FABP7 | O15540 | 2/20 | 0.43 |
| ▸ | CASP3 | P42574 | 3/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14416228 | 1.00 | KMT2A (0.47) | KMT2AFABP5FABP7CASP3CA1 | |
| SCHEMBL16128277 | 0.89 | CASP3 (0.50) | KMT2AFABP5FABP7CASP3CA1 | |
| SCHEMBL15223383 | 0.87 | KMT2A (0.45) | KMT2AFABP5FABP7CASP3CA1 | |
| SCHEMBL29966663 | 0.85 | KMT2A (0.51) | KMT2AFABP5FABP7CASP3CA1 | |
| SCHEMBL15318692 | 0.85 | KMT2A (0.51) | KMT2AFABP5FABP7CASP3CA1 | |
| SCHEMBL29743094 | 0.83 | KMT2A (0.42) | KMT2AFABP5FABP7CASP3CA1 | |
| SCHEMBL29823514 | 0.83 | KMT2A (0.46) | KMT2AFABP5FABP7CASP3CA1 | |
| SCHEMBL16128286 | 0.83 | FABP5 (0.48) | KMT2AFABP5FABP7CASP3CA1 | |
| SCHEMBL29392800 | 0.83 | FABP5 (0.48) | KMT2AFABP5FABP7CASP3CA1 | |
| SCHEMBL29823827 | 0.82 | KMT2A (0.50) | KMT2AFABP5FABP7CASP3CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118184792-A | Paucimannose specific antibody preparation and detection kit | 苏州海闾糖生物科技有限公司 | 2024-06-14 | — | — | CN | claimed |
| US-12606634-B2 | Antibody-pyrrolobenzodiazepine derivative conjugate which binds caludin-6 and claudin-9 | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2026-04-21 | — | — | US | disclosed |
| EP-4631954-A1 | METHOD FOR SEPARATING GLYCOPEPTIDES | KH Neochem Co., Ltd. (JP) | 2025-10-15 | — | — | EP | disclosed |
| CN-120536527-A | Catalytic synthesis preparation of Le-containing materialxNovel method for epitope oligosaccharide | 江苏省血吸虫病防治研究所 | 2025-08-26 | — | — | CN | disclosed |
| CN-120536526-A | Method for preparing helminth oligosaccharide product by utilizing glycosyltransferase cascade catalysis | 江苏省血吸虫病防治研究所 | 2025-08-26 | — | — | CN | disclosed |
| US-12383605-B2 | Exenatide analog and use thereof | ANYGEN CO., LTD. (KR) | 2025-08-12 | — | — | US | disclosed |
| EP-4582106-A1 | ANTIBODY-DRUG CONJUGATE INCLUDING MUTANT FC REGION | Daiichi Sankyo Company, Limited (JP) | 2025-07-09 | — | — | EP | disclosed |
| US-12350344-B2 | Methods of treating a tumor by administering a claudin-6 (CLDN6) or CLDN9 antibody-pyrrolobenzodiazepine derivative conjugate | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-07-08 | — | — | US | disclosed |
| US-20250114647-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING SUBSTITUTED BENZO[e]PYRROLO[1,2-a][1,4]DIAZEPINES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-04-10 | — | — | US | disclosed |
| CN-119744182-A | Antibody drug conjugates comprising a mutant Fc region | 第一三共株式会社 | 2025-04-01 | — | — | CN | disclosed |
| US-11583590-B2 | Antibody-pyrrolobenzodiazepine derivative conjugate and method of use thereof for treating a tumor | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-02-21 | — | — | US | disclosed |
| US-20220395579-A1 | ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-12-15 | — | — | US | disclosed |
| WO-2022255289-A1 | METHOD FOR PRODUCING GLYCOPEPTIDE | ＫＨネオケム株式会社 | 2022-12-08 | — | — | WO | disclosed |
| CN-115380043-A | Exenatide analogue and application thereof | 安医健有限公司 | 2022-11-22 | — | — | CN | disclosed |
| US-20220323548-A1 | EXENATIDE ANALOG AND USE THEREOF | ANYGEN CO., LTD., (KR) | 2022-10-13 | — | — | US | disclosed |
| WO-2022163846-A1 | NOVEL METHOD FOR PRODUCING ANTIBODY-IMMUNOSTIMULATOR CONJUGATE | 第一三共株式会社 | 2022-08-04 | — | — | WO | disclosed |
| US-20220177601-A1 | ANTI-HER2 ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-06-09 | — | — | US | disclosed |
| US-20220168440-A1 | ANTIBODY-PYRROLOBENZODIAZEPINE DEPRIVATIVE CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-06-02 | — | — | US | disclosed |
| US-20220168438-A1 | COMBINATION OF ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE AND PARP INHIBITOR | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-06-02 | — | — | US | disclosed |
| US-20220125943-A1 | ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12383605-B2 | Exenatide analog and use thereof | GLP1R, IAPP, GIPR | KMT2A 3078/4885FABP5 1240/4885FABP7 1984/4885 |
| US-12606634-B2 | Antibody-pyrrolobenzodiazepine derivative conjugate which binds caludin-6 and claudin-9 | SIGLEC9, DSG1, VSIG8 | KMT2A 3198/4885FABP5 828/4885FABP7 487/4885 |
| US-20220168440-A1 | ANTIBODY-PYRROLOBENZODIAZEPINE DEPRIVATIVE CONJUGATE | CD79B, BTD, PDCD1 | KMT2A 446/4885FABP5 1330/4885FABP7 443/4885 |
| US-12350344-B2 | Methods of treating a tumor by administering a claudin-6 (CLDN6) or CLDN9 antibody-pyrrolobenzodiazepine derivative conjugate | EPCAM, PDCD6, JUP | KMT2A 2405/4885FABP5 389/4885FABP7 77/4885 |
| US-20220168438-A1 | COMBINATION OF ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE AND PARP INHIBITOR | PARP2, PARP3, PARP1 | KMT2A 415/4885FABP5 2923/4885FABP7 2554/4885 |
| US-20220125943-A1 | ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE | PDCD6, EPCAM, CNTN1 | KMT2A 1977/4885FABP5 568/4885FABP7 85/4885 |
| US-20220323548-A1 | EXENATIDE ANALOG AND USE THEREOF | GLP1R, IAPP, GIPR | KMT2A 3078/4885FABP5 1240/4885FABP7 1984/4885 |
| US-20250114647-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING SUBSTITUTED BENZO[e]PYRROLO[1,2-a][1,4]DIAZEPINES | CNTN1, BTN3A1, FABP6 | KMT2A 3126/4885FABP5 342/4885FABP7 52/4885 |
| US-11583590-B2 | Antibody-pyrrolobenzodiazepine derivative conjugate and method of use thereof for treating a tumor | EPCAM, PDCD6, CNTN1 | KMT2A 2063/4885FABP5 562/4885FABP7 64/4885 |
| US-20220177601-A1 | ANTI-HER2 ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE | ERBB2, BRD2, PA2G4 | KMT2A 385/4885FABP5 1284/4885FABP7 684/4885 |
| US-20220395579-A1 | ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE | PDCD6, EPCAM, CNTN1 | KMT2A 1977/4885FABP5 568/4885FABP7 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.